Neuland Laboratories
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Neuland Laboratories is strategically evolving from a manufacturing-centric model to an innovation-driven CDMO partner, as highlighted by management's focus on expanding its custom manufacturing solutions (CMS) and investing in R&D infrastructure. This shift is expected to enhance revenue visibility and profitability, supported by a robust order book and deepening partnerships with pharmaceutical innovators. Vista's financial outlook anticipates stable revenue growth and improving margins, reflecting the positive impact of these strategic initiatives. The company's conservative balance sheet and fair valuation align with its intrinsic value, suggesting a favorable risk-reward profile. However, potential headwinds include the inherent lumpiness of outsourcing programs and geopolitical complexities that could affect operational execution. Overall, Neuland is well-positioned to capitalize on industry tailwinds, including the growing demand for complex modalities and the shift towards resilient supply chains. Over the next 12-24 months, key opportunities lie in scaling peptide manufacturing and enhancing R&D capabilities, while watchpoints include maintaining operational discipline amidst aggressive expansion efforts
Why We Like This Stock
- Strategic shift towards complex modalities and custom manufacturing solutions enhances revenue visibility
- Robust order book and deepening relationships with pharmaceutical innovators support stable revenue growth
- Investments in R&D infrastructure are expected to improve margins and long-term value creation
Things To Watch Out For
- The business remains inherently lumpy due to reliance on a concentrated portfolio of commercial molecules
- Geopolitical and regulatory complexities may pose risks to operational execution
- Short-term pressure on ROCE could arise from aggressive capital expenditure
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,559 | 1,477 | 2,023 | 2,536 | 3,126 |
| Profit Before Tax (Cr.) | 401 | 277 | 489 | 728 | 862 |
| PBT Margin | 25.7% | 18.8% | 24.2% | 28.7% | 27.6% |
| Net Profit (Cr.) | 302 | 220 | 360 | 533 | 631 |
| Earnings Per Share | 233.9 | 170.9 | 279.1 | 413.1 | 489.1 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Goldman Sachs | ▲ Buy | 23,300 | 06-Aug-2026 |
Company Overview
Show Company Profile
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.